Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 20;8:754254. doi: 10.3389/fcvm.2021.754254

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Salybekov, Salybekova, Sheng, Shinozaki, Yokoyama, Kobayashi and Asahara.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immunomodulatory effect of RACev. (A) The body weights of all three groups were similar across the study period. (B) Spleen weight mass at days 4 and 28 days after myocardial ischemia reperfusion injury was not different among the three groups. (C–F) Peripheral blood-derived CD4, CD8, Treg, and CD11b/c cells were not elevated, indicating immune tolerance effect of RACev. (G–K) Spleen-derived immune reaction or response biomarkers such as CD4, TNK, iNK, and antigen-presenting cells were evaluated and did not change among the three groups. Statistical significance was determined using the One-way ANNOVA followed by Dunn's multiple comparisons post-hoc test. The results are presented as mean ± SEM (n = 8–10 per group).